A Two-Part Single and Multiple Ascending Dose Trial of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LBT-3627 in Healthy Participants and in Participants With Parkinson's Disease.
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Parkinson Disease
In brief
Phase I a/b SAD/MAD study to evaluate safety and tolerability of LBT-3627 in both healthy volunteers and Parkinson's patients.
Key facts
- Study ID
- NCT06466525
- Run by
- Longevity Biotech Australia Pty Ltd (subsidiary)
- People needed
- 64
- Starts
- 2024-07-16
- Expected to finish
- 2025-10-01
- Last updated by the study team
- 2025-05-13
Who can join
Age: 30 and older, up to 89. Sex: any. Healthy volunteers: accepted.
Where it is running
- Alfred Hospital — Melbourne, Victoria, Australia (enrolling)
- Nucleus Networks — Melbourne, Victoria, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.